EU Commission approves new subcutaneous version of Tocilizumab for RA patients

01 May 2014

  • The drug will be available soon via a prefilled syringe so patients can choose to self-inject Tocilizumab at home, as an alternative to having it administered intravenously by HCPs.
  • The EU ruling details that subcutaneous Tocilizumab is suitable for the treatment of moderate to severe rheumatoid arthritis in patients who are either intolerant to or have failed to respond to other therapies.
  • Tocilizumab is now the first anti IL-6 receptor biologic available in subcutaneous and intravenous formulations, for both monotherapy applications and for use in combination with methotrexate.

Ailsa Bosworth, Chief Executive of the National Rheumatoid Arthritis Society, said:

“I welcome the introduction of sub- cutaneous Tocilizumab. This will provide patients with increased choice of mode of administration to suit their lifestyle. Many people prefer to be able to inject at home rather than taking time off work to attend hospital for infusion.”